SCAAR Data Shows Edge For Taxus DES In Diabetics; More Studies Needed
This article was originally published in The Pink Sheet Daily
Executive Summary
Boston Scientific's Taxus paclitaxel-eluting stents are more effective than their competitors in diabetic patients in the SCAAR registry, but the results need to be confirmed in prospective randomized trials, the authors conclude.